BioMarin Earnings Call Highlights Growth, Pipeline, Deals
Biomarin Pharmaceutical Inc. ((BMRN)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BioMarin Pharmaceutical’s latest earnings call struck a confident tone, with management highlighting record 2025 revenue, accelerating profitability and strong cash generation. Executives balanced this optimism with candid discussion of near-term headwinds, including the Roctavian withdrawal, royalty declines and Q1 softness, but argued that durable growth drivers and recent acquisitions set up a stronger multi-year trajectory.
Record Revenue Underscores Growth Trajectory
BioMarin reported 2025 revenue of $3.22 billion, up 13% year over year and the highest in the company’s history. Fourth-quarter sales grew even faster at 17% to $875 million, underscoring solid demand into year-end despite some timing-related boosts that will not repeat in early 2026.
Voxzogo’s Global Expansion Drives Momentum
Voxzogo remained the primary growth engine, with full-year sales climbing 26% to $927 million and Q4 revenue jumping 31%. About 73% of Voxzogo revenue, roughly $680 million, was generated outside the U.S., and more than 5,000 children were on therapy worldwide by year-end.
Enzyme Therapies Prove Durable and Scalable
The company’s enzyme therapy portfolio delivered 9% revenue growth in 2025, with a strong 13% year-over-year increase in the fourth quarter. Management described this franchise as a more than $2 billion business spanning about 80 countries, highlighting its resilience and global diversification.
Palynziq Beats Expectations and Eyes Label Expansion
Palynziq posted standout growth, with revenue rising 22% for the year and 25% in the fourth quarter. Management pointed to a pending U.S. label expansion into adolescents, with a regulatory decision expected in early 2026, as a potential catalyst for further uptake in the phenylketonuria market.
Profitability and Cash Flow Strengthen Balance Sheet
Non-GAAP diluted EPS for 2025 reached $3.15, while underlying business EPS, excluding R&D and Roctavian-related charges, grew about 34%. Operating cash flow surged 45% to $828 million, providing ample capacity to fund pipeline investments and support the company’s acquisition strategy.
Pipeline Milestones Support Long-Term Growth Story
BioMarin highlighted a robust slate of upcoming R&D catalysts, including Phase III readouts for Voxzogo in hypochondroplasia and BMN 401 in ENPP1 deficiency. BMN 333 is moving into a Phase II/III program, and BMN 351 reported 5% mean absolute dystrophin at week 25, with further cohorts enrolling and steady-state levels expected to be higher.
Strategic Acquisitions Bolster Rare-Disease Portfolio
The acquisition of Inozyme brings BMN 401 fully into the fold, while the planned purchase of Amicus adds Galafold, Pombiliti and Opfolda and is expected to close in the second quarter of 2026. Management secured about $3.7 billion of debt financing on favorable terms to fund the Amicus deal, which they see as materially uplifting revenue beyond 2026.
Commercial Execution and International Penetration Impress
Executives showcased strong commercial execution, citing roughly 40% penetration within seven months in a key Asia Pacific launch and around 70% penetration within 12 months in a midsized European market. The company is sharpening its focus on infants aged zero to two and on fast-growing ex-U.S. regions, which already account for approximately three-quarters of Voxzogo revenue.
Roctavian Exit and One-Off Charges Clarified
BioMarin formally withdrew Roctavian from the market and booked about $240 million of special GAAP items in the fourth quarter of 2025. Roughly half of this related to inventory write-offs that were not excluded from non-GAAP earnings, helping investors better understand the underlying performance of the core business.
Q4 Order Timing Sets Up a Soft First Quarter
Fourth-quarter results benefited from a roughly $30 million contracted government order for Voxzogo as well as stocking increases across multiple products. Management does not expect these factors to recur in the first quarter of 2026 and has flagged Q1 as the lowest revenue quarter of the year.
Royalty Declines Create a 2026 Growth Headwind
Royalty income from KUVAN and Roctavian is expected to fall sharply in 2026, with management guiding to only $100 million to $125 million from these streams. They estimate this drop will represent about a 3% headwind to total revenue growth when compared with 2025 levels.
Voxzogo Faces Emerging Competitive Threats
The company acknowledged new competitors on the horizon, including oral FGFR3 inhibitors that could eventually compete with Voxzogo. While near-term switching is expected to be limited for well-managed patients, BioMarin incorporated potential competitive pressure into its guidance and warned that growth could moderate over time.
Market Access and Pricing Present Tactical Risks
Management described 2026 as a year of routine market-access renegotiations in a handful of countries, with the possibility of price resets. While these talks may create short-term revenue pressure, the company framed them as opportunities to broaden patient access and deepen market penetration over the long term.
Amicus Deal Brings Near-Term Dilution and Costs
The planned Amicus acquisition will weigh modestly on 2026 earnings, with about $0.25 per share in pre-close integration and interest costs already reflected in guidance. Most of these expenses will hit in the first quarter, contributing to Q1 being the lowest EPS quarter of the year even as the transaction is expected to enhance growth beyond 2026.
Guidance Signals Steady Growth and Margin Expansion
For 2026, excluding post-close contributions from Amicus, BioMarin guided to total revenue of $3.325 billion to $3.425 billion, driven by enzyme therapies of $2.225 billion to $2.275 billion and Voxzogo of $975 million to $1.025 billion. Non-GAAP diluted EPS is projected at $4.95 to $5.15 with an organic operating margin around 40%, though the Amicus deal could temporarily nudge margins slightly below that threshold.
BioMarin’s earnings call painted a picture of a rare-disease leader leveraging strong commercial franchises, a deep pipeline and targeted acquisitions to fuel growth. While investors will need to monitor early 2026 softness, royalty declines and competitive dynamics, management’s transparent guidance and improving profitability suggest the long-term story remains firmly intact.
